Compare Flux Power Holdings Inc (FLUX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Incyte Corporation — how do they compare? Flux Power Holdings Inc trades at $0.48 (market cap $9.97M), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2291.9× Flux Power Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Incyte Corporation for 33 Days on average.
| FLUX | INCY | |
|---|---|---|
Market Cap | $9.97M | $22.85B |
Volume | 817,320 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $6.66 | $129.93 |
52-Week Low | $0.41 | $83.80 |
Typical Hold Time | 20 Days | 33 Days |
Enterprise Value | $18.18M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4612, down 5.92% today, with a bearish technical signal despite unanimous analyst buy ratings. The company reported declining revenue from $66M in 2025 to $42M in 2026 while maintaining a net loss of -$7M. Recent news highlights a rejected acquisition offer from Solidion Technology, creating uncertainty around strategic direction.
The stock faces fundamental challenges with negative profitability metrics but maintains a low P/S ratio of 0.22. Investment opportunity exists if operational improvements materialize, while risks include persistent losses and acquisition-related volatility. Analyst consensus remains optimistic with 6 buy ratings despite recent earnings misses.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
